Teclistamab versus real-world physician's choice of therapy in triple-class exposed relapsed/refractory multiple myeloma
Aim: We compared the effectiveness of teclistamab versus real-world physician's choice of therapy (RWPC) in triple-class exposed relapsed/refractory multiple myeloma. Materials & methods: MajesTEC- 1 eligibility criteria were applied to the RWPC cohort. Baseline covariate imbalances were ad...
Enregistré dans:
| Auteurs principaux: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Livre |
| Publié: |
Becaris Publishing Limited,
2023-04-01T00:00:00Z.
|
| Sujets: | |
| Accès en ligne: | Connect to this object online. |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
MARC
| LEADER | 00000 am a22000003u 4500 | ||
|---|---|---|---|
| 001 | doaj_d2234f01c82748d787b0b8d1a00b2e7e | ||
| 042 | |a dc | ||
| 100 | 1 | 0 | |a Amrita Krishnan |e author |
| 700 | 1 | 0 | |a Ajay K Nooka |e author |
| 700 | 1 | 0 | |a Ajai Chari |e author |
| 700 | 1 | 0 | |a Alfred L Garfall |e author |
| 700 | 1 | 0 | |a Thomas G Martin |e author |
| 700 | 1 | 0 | |a Sandhya Nair |e author |
| 700 | 1 | 0 | |a Xiwu Lin |e author |
| 700 | 1 | 0 | |a Keqin Qi |e author |
| 700 | 1 | 0 | |a Anil Londhe |e author |
| 700 | 1 | 0 | |a Lixia Pei |e author |
| 700 | 1 | 0 | |a Eric Ammann |e author |
| 700 | 1 | 0 | |a Rachel Kobos |e author |
| 700 | 1 | 0 | |a Jennifer Smit |e author |
| 700 | 1 | 0 | |a Trilok Parekh |e author |
| 700 | 1 | 0 | |a Alexander Marshall |e author |
| 700 | 1 | 0 | |a Mary Slavcev |e author |
| 700 | 1 | 0 | |a Saad Z Usmani |e author |
| 245 | 0 | 0 | |a Teclistamab versus real-world physician's choice of therapy in triple-class exposed relapsed/refractory multiple myeloma |
| 260 | |b Becaris Publishing Limited, |c 2023-04-01T00:00:00Z. | ||
| 500 | |a 10.57264/cer-2022-0186 | ||
| 500 | |a 2042-6313 | ||
| 520 | |a Aim: We compared the effectiveness of teclistamab versus real-world physician's choice of therapy (RWPC) in triple-class exposed relapsed/refractory multiple myeloma. Materials & methods: MajesTEC- 1 eligibility criteria were applied to the RWPC cohort. Baseline covariate imbalances were adjusted using inverse probability of treatment weighting. Overall survival, progression-free survival and time to next treatment were compared. Results: After inverse probability of treatment weighting, baseline characteristics were similar between cohorts (teclistamab, n = 165; RWPC, n = 364 [766 observations]). Teclistamab treated patients had numerically better overall survival (hazard ratio [HR]: 0.82 [95% CI: 0.59- 1.14]; p = 0.233) and significantly greater progression-free survival (HR: 0.43 [0.33-0.56]; p < 0.0001) and time to next treatment (HR: 0.36 [0.27-0.49]; p < 0.0001) versus the RWPC cohort. Conclusion: Teclistamab offered clinical benefit over RWPC in triple-class exposed relapsed/refractory multiple myeloma. | ||
| 546 | |a EN | ||
| 690 | |a b-cell maturation antigen | ||
| 690 | |a bispecific antibody | ||
| 690 | |a comparative effectiveness | ||
| 690 | |a indirect treatment comparison | ||
| 690 | |a majestec-1 | ||
| 690 | |a Public aspects of medicine | ||
| 690 | |a RA1-1270 | ||
| 655 | 7 | |a article |2 local | |
| 786 | 0 | |n Journal of Comparative Effectiveness Research, Vol 12, Iss 6 (2023) | |
| 787 | 0 | |n https://doaj.org/toc/2042-6313 | |
| 856 | 4 | 1 | |u https://doaj.org/article/d2234f01c82748d787b0b8d1a00b2e7e |z Connect to this object online. |